Hikma和Celltrion伙伴在中东和北非地区推广负担得起的生物相似物。 Hikma and Celltrion partner to expand affordable biosimilars in MENA region.

Hikma制药公司和Celltrion公司签署了独家许可证协议,以便在中东和北非扩大六种生物类治疗的覆盖面,重点是肿瘤学、免疫疾病和其他条件。 Hikma Pharmaceuticals and Celltrion Inc. have signed exclusive licensing deals to expand access to six biosimilar treatments across the Middle East and North Africa, focusing on oncology, immune diseases, and other conditions. Hikma将处理本区域的商业化问题,而Celltrion则负责管理发展和供应。 Hikma will handle commercialization in the region, while Celltrion manages development and supply. 该伙伴关系旨在增加负担得起的、高质量的生物治疗,改善患者获得治疗的机会,并加强医院治疗标准。 The partnership aims to increase affordable, high-quality biologic therapies, improve patient access, and strengthen hospital treatment standards.